Merrimack Pharmaceuticals Inc (MACK.OQ)
18 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|64||2017||Chairman of the Board|
|54||2017||President, Chief Executive Officer, Director|
|50||2017||Chief Financial Officer,Principal Financial Officer, Principal Accounting Officer, Treasurer|
|2017||Head of Human Resources|
- BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33
- BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results
- BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer
- BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121
- BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln